Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis

-  The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis.-  Preclinical data, including higher oral exposure, longer half-life and strong efficacy, support ASC50 as a potential best-in-class once-daily oral agent for the treatment of psoriasis.HONG KONG, June 17, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that the first healthy participants have been dosed in a randomized, double-blind, placebo-controlled Phase ...